Dr. Arvind Bhandari, M.D.
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 53
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 313
Licensed in Texas since 1978, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
TX license F0883 (first issued 1978; active) -
Hematology & Oncology Physician
TX license F0883 (first issued 1978; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Memorial Hermann Hospital System Houston, TX
- Houston Methodist Sugarland Hospital Sugar Land, TX
- Memorial Hermann Sugar Land Hospital Sugar Land, TX
Medical groups
- Texas Oncology PA (1,014 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 313
- Services billed
- 39,508
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 4,860 | 11 |
| Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 4,400 | 39 |
| Injection, fosaprepitant, 1 mg | 3,600 | 12 |
| Injection, dexamethasone sodium phosphate, 1 mg | 710 | 16 |
| Insertion of needle into vein for collection of blood sample | 665 | 177 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 607 | 174 |
| Injection, palonosetron hcl, 25 mcg | 330 | 13 |
| Established patient office or other outpatient visit, 30-39 minutes | 309 | 120 |
| Established patient office or other outpatient visit, 20-29 minutes | 197 | 105 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 117 | 26 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Xarelto (rivaroxaban) Other prescribers in Sugar Land, TX | 51 |
| Revlimid (lenalidomide) | 50 |
| Eliquis (apixaban) Other prescribers in Sugar Land, TX | 43 |
| Hydroxyurea Other prescribers in Sugar Land, TX | 37 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Sugar Land, TX | 34 |
| Warfarin Sodium Other prescribers in Sugar Land, TX | 28 |
| Anastrozole Other prescribers in Sugar Land, TX | 26 |
| Acyclovir Other prescribers in Sugar Land, TX | 24 |
| Pomalyst (pomalidomide) | 23 |
| Letrozole Other prescribers in Sugar Land, TX | 22 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 10 payments worth $563 in total to this clinician.
| Daiichi Sankyo Inc. | $278 |
|---|---|
| Janssen Biotech, Inc. | $163 |
| AstraZeneca Pharmaceuticals LP | $53.72 |
| Merck Sharp & Dohme LLC | $34.18 |
| Astellas Pharma US Inc | $18.47 |
| Cycle Pharmaceuticals Inc | $15.73 |
| Food and Beverage | $563 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.